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Olle Ringden, Behnam SadeghiAllogeneic hematopoietic stem cell transplantation
(HSCT), an established therapy for treatment of leu-
kemia and other hematologic malignancies, is the
most effective way to demonstrate that the immune
system may control cancer. The so-called ‘‘graft-
versus-leukemia’’ (GVL) effect has been demonstrated
in experimental animals and in several clinical studies
[1]. From the clinical studies, it seems that chronic
graft-versus-host disease (GVHD) has a more potent
GVL effect than acute GVHD [1,2]. However,
GVHD is associated with high morbidity and
mortality, and in several studies the best long-term
leukemia-free survival (LFS) was seen in patients
with mild acute and mild chronic GVHD [1,3].
The aim of myeloablative conditioning (MAC)
before HSCT is to kill as many leukemic cells as pos-
sible and rescue the patient with a hematopoietic graft
from a healthy donor. A limitation of MAC is toxicity
to several organs. Reduced-intensity conditioning
(RIC) was introduced to overcome some of the toxicity
induced byMAC and allow the use of HSCT in elderly
patients and those with comorbidities who otherwise
would not be candidates for HSCT [4]. RIC is less
dependent on the antitumor effect of high-dose
chemoradiotherapy and takes advantage of the GVL
effect induced by immunocompetent cells in the
healthy donor graft. Donor lymphocyte infusion can
further potentiate the GVL effect [5].
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than 5000 patients with acute myelogenous leukemia
(AML) or myelodysplastic syndrome (MDS) who un-
derwent HSCT with a MAC or RIC regimen [6].
This is the largest study of GVL comparing MAC
and RIC published to date.
The patients were divided into 4 groups: those
without GVHD, those with acute GVHD alone, those
with chronic GVHD alone, and those with both acute
and chronic GVHD. In the first analysis, all patients
were included, and acute and chronic GVHD were
treated as time-dependent covariates. Multivariate
analysis identified a decreased likelihood of relapse as-
sociated with both MAC and RIC in patients with
chronic GVHD only and those with both acute and
chronic GVHD. However, among patients with acute
GVHD only, those who received RIC had a signifi-
cantly lower probability of relapse (P\ .0001) com-
pared with those who received MAC, in whom acute
GVHD only had no impact on the probability of re-
lapse (P 5 .16). This finding suggests that acute
GVHD should be avoided in patients receiving MAC,
but mild or moderate acute GVHD may be beneficial
in patients treated with RIC. In bothMAC and RIC re-
cipients, transplantation-related mortality (TRM) was
increased in all patients with any form of GVHD (P
\ .0001). Taken together, these findings indicate that
an increased impact of GVHD on relapse and TRM
(ie, treatment failure) in patients with acute GVHD
onlywho received eitherMACorRIC.However, in pa-
tients with acute and chronicGVHD, treatment failure
was increased in those receiving MAC (hazard ratio
[HR] 1.5; P\ .0001), but not in those treated with
RIC (RR, 1.19; P 5 .11). This significant finding sug-
gests that patients with acute and chronic GVHD
have improved LFS when conditioned with RIC, but
not when conditioned withMAC. Thismay be because
MAC is more toxic, and thus may be associated with
more critical and severe GVHD as opposed the acute
and chronic GVHD in patients treated with RIC.
Survival was decreased in patients with acute
GVHD only regardless of whether they were treated
with MAC or RIC (P\ .0001). In the MAC recipients,
survival did not differ significantly between those with1615
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(P 5 .90). However, in the RIC recipients, survival
was improved in those with chronic GVHD only (HR,
0.74; P 5 .007). In the patients with acute and chronic
GVHD, MAC was associated with decreased survival
(HR, 1.37; P\ .0001). In contrast, in RIC recipients,
there was no statistically significant difference in sur-
vival between those without GVHD and those with
both acute and chronic GVHD (HR, 1.13; P5 .22).
This large study demonstrates that the GVL effect
is more effective in RIC recipients by reducing treat-
ment failure and improving survival in comparison
with MAC recipients. This is a modern material with
a large cohort of patients and so must be taken seri-
ously. Of course, some caution is necessary, given
this study’s limitations typically associated with retro-
spective multicenter studies.
The second analysis was a landmark analysis of
more than 2000 patients who survived at least 1 year
disease-free after HSCT. In the MAC recipients, no
GVL effect of acute or chronic GVHD was evident
in any of the 3 GVHD groups. In contrast, RIC recip-
ients with both acute and chronic GVHD had a signif-
icantly reduced probability of relapse (HR, 0.44; P 5
.009). In this landmark analysis, TRM was increased
in all MAC recipients with any form of GVHD, but
only in RIC recipients with both acute and chronic
GVHD (P5 .002). Taken together, these findings in-
dicate increased treatment failure in MAC recipients
with chronic GVHD only and with both acute and
chronic GVHD. In the RIC recipients, 1-year
disease-free survivors in all of the GVHD groups dem-
onstrated no increase in treatment failure compared
with those without GVHD. Overall survival was de-
creased in the MAC recipients with chronic GVHD
only (P 5 .0001) and with both acute and chronic
GVHD (P\ .0001). In contrast, overall survival was
not significantly different in RIC recipients without
GVHD and those with acute GVHD only or chronic
GVHD only, but was decreased in those with both
acute and chronic GVHD (P 5 .018).
This study suggests that the GVL effect is stronger
and less harmful with RIC, not only in survivors during
the first year after HSCT, but also in those living
disease-free after 1 year posttransplantation. Thus,
the long-term GVL effect is apparently more benefi-
cial with RIC as opposed to MAC. Several large regis-
try studies that compared outcomes in patients with
AML and MDS who received MAC or RIC found es-
sentially lower TRM and an increased relapse rate in
RIC recipients comparedwithMAC recipients, similar
LFS and survival in the 2 groups [7-9].
As Weisdorf et al. show, RIC seems to be associ-
ated with a stronger GVL effect, with less toxicity
and suffering in the early posttransplantation period.
Because LFS and survival do not differ in patients
treated with RIC or MAC, RIC may be preferredoverMAC in patients in remission. InMAC recipients,
no beneficial effects of acute and chronic GVHD on
improving LFS or survival were noted compared
with patients without GVHD [6]. AGVL effect occurs
in the absence of acute GVHD; thus, GVHD probably
should be avoided in patients receiving MAC [1].
However, the grade of acute and chronic GVHD was
not considered in the present analysis, and the possibil-
ity remains that mild acute and chronic GVHD are
beneficial in HSCT recipients treated with MAC, as
reported previously [1]. HSCT without severe acute
GVHD can be achieved through T cell depletion
of the graft or long-term immunosuppression with
anti–T cell immunoglobulin [1]. However, T cell de-
pletion is associated with increased risk of leukemic re-
lapse unless conditioning is intensified [1,10]. It is also
possible to induce mild acute andmild chronic GVHD
by giving low-dose cyclosporine and then discontinue
immunosuppression after 3-4 months in the absence of
GVHD, as has been done in recipients of HLA-
identical sibling transplants [11]. This approach
resulted in increased mild acute GVHD, increased
probability of chronic GVHD, decreased leukemic re-
lapse, and improved LFS and survival. According to
the present CIBMTR study, this approach may be
even more successful and safer in recipients of RIC.
Several previous studies have reported a reduced
probability of acute and chronic GVHD with RIC
compared with MAC [7,12]. One explanation for this
finding may be that toxicity induced by the regimen
triggers and paves the way for GVHD [1,13-15].
From the present CIBMTR study, it seems that
acute and/or chronic GVHD that does occur is
better tolerated by RIC recipients than by MAC
recipients [6].
In conclusion, this large CIBMTR study suggests
that the GVL effect in patients with AML or MDS is
more optimal—that is, results in improved survival
and LFS (both short-term and long-term)—when
using RIC as opposed to MAC. The data suggest
that RIC should be selected more often as condition-
ing for good-risk patients with AML andMDS. A pro-
spective randomized study is warranted to confirm
these data.REFERENCES
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Marrow Transplant. 2008;42:807-818.Immune Recovery after Allogeneic Hematopoietic Stem
Cell Transplantation: Is It Time to Revisit How Patients
Are Monitored?
Miguel-Angel Perales, Marcel R. M. van den BrinkAllogeneic hematopoietic stem cell transplanta-
tion (allo-HSCT) is associated with deficiencies in T
and B cell reconstitution that can persist for over
a year and have been linked to increased risks of infec-
tions [1-4], disease relapse [5], and the development of
secondary malignancies [6]. Posttransplantation im-
mune reconstitution is affected by several factors, in-
cluding thymic involution associated with advanced
patient age, the conditioning regimen, HLA disparity
between donor and recipient, T cell depletion of
the graft, occurrence of graft-versus-host disease
(GVHD), and the drugs used to prevent or treat
GVHD. Total body irradiation (TBI), for example,
decreases the production of IL-7 by thymic stromal
cells, suggesting that radiation may affect normal T
cell regeneration driven by IL-7 [7]. In addition, ap-
proaches used to prevent GVHD through in vivo
(with alemtuzumab or antithymocyte globulin, ATG)
or in vitro T cell depletion also have a significant im-
pact on T cell recovery [1,8-17]. Finally, GVHD hasbeen shown to affect the thymus [18-20], and also
has a significant impact on immune recovery due to
immunosuppressive drugs required to treat GVHD
[21-26].
Different approaches have been used to assess post-
transplantation immune recovery, from relatively sim-
ple and readily available parameters such as absolute
lymphocyte count (ALC) or counts of lymphocyte sub-
sets (CD41 and CD81 T cells, NK cells, B cells), to
more complex and less routine assays of T cell reper-
toire and T cell receptor–expressing circles (TRECs)
[1-4,15-18,27-30]. ALC has been shown to be
predictive of overall survival and relapse in several
studies [15,27-30], whereas CD41 T cell count has
been shown to correlate with an increased risk of fatal
opportunistic infections [1,16]. Studies of TRECs,
which can be used as markers of thymopoiesis, have
shown more rapid recovery in younger recipients and
in recipients of conventional grafts compared to T
cell–depleted grafts [17], whereas the occurrence ofYork Avenue, Box 298, New York, NY 10065 (e-mail:
peralesm@mskcc.org).
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